Galapagos awarded European Union grant
December 04 2006 - 1:01AM
UK Regulatory
Mechelen, Belgium; 4 December 2006 - Galapagos NV (Euronext & LSE:
GLPG) has secured a European Union grant of �500,000 for service
division BioFocus DPI's participation in PROLIGEN, a research
consortium focused on enhancing regeneration of injured kidneys.
The PROLIGEN consortium, comprising a number of European companies
and universities, aims to improve the regenerative capacity of
injured kidneys, using information derived from genomics, proteomics,
and functional genomics. Under the terms of the agreement, BioFocus
DPI will use its SilenceSelect and FLeXSelect adenoviral libraries
and cellular assay expertise to identify targets that can serve as
starting points for the development of novel treatment methods for
kidney injury. The resulting gene function information will provide
the PROLIGEN consortium the necessary tools to deliver new
biologicals and cell-based therapies for kidney regeneration.
"That Galapagos' core target discovery engine can play such a central
role in the EU's new kidney regeneration research effort is
gratifying and provides strong support for its potential application
in other areas of unmet medical need," said Onno van de Stolpe, CEO
of Galapagos.
About PROLIGEN
The PROLIGEN consortium brings together selected academics,
clinicians, and industry experts to deliver new therapeutic
approaches to regenerative medicine. Consortium members include the
Consejo Superior de Investigaciones Cient�ficas - Instituto de
Investigaciones Biom�dicas de Barcelona and the Fundaci� Privada
Institut d'Investigaci� Biom�dica de Bellvitge in Spain, the Klinikum
der Johann Wolfgang Goethe Universit�t in Germany, Genedata AG in
Switzerland, ProtEra s.r.l. in Italy, Leiden University and BioFocus
DPI in the Netherlands. PROLIGEN's approach is to define and
identify a set of proteins associated with functional recovery from
renal injury, build up high throughput test systems to follow the
basic biological process involved in regeneration and use these read
out systems to identify novel targets, followed by development of
biologicals and cell based therapy for the regeneration of injured
kidneys. The European Union's Sixth Framework Program is supporting
PROLIGEN's efforts with �2.5 million in funding over three years.
About Galapagos
Galapagos is a publicly traded, genomics-based drug discovery company
(Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA, London AiM:
GLPG) that has drug discovery programs based on proprietary, novel
targets in bone and joint diseases - osteoarthritis, osteoporosis and
rheumatoid arthritis. Galapagos offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies through its division BioFocus DPI, encompassing
target discovery and drug discovery services through to delivery of
pre-clinical candidates. In addition, BioFocus DPI provides
adenoviral reagents for rapid identification and validation of novel
drug targets and compound libraries for drug screening. Galapagos
currently employs more than 330 people, including 144 PhDs, and
operates facilities in seven countries, with global headquarters in
Mechelen, Belgium. More information about Galapagos and BioFocus DPI
can be found at www.glpg.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans", "seeks," "estimates,"
"may," "will," "could," and "continues," as well as similar
expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause the
actual results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
This communication reflects only the view of Galapagos NV. The
European Union is not liable for any use that may be made of the
information contained in this press release.
SilenceSelect� and FLeXSelect� are registered trademarks of Galapagos
NV and/or its affiliates.
- ---END OF MESSAGE---
Copyright � Hugin ASA 2006. All rights reserved.
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024